
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is a biopharmaceutical company with a strong pipeline and a unique particle engineering platform technology that sets it apart from its competitors. With a promising drug in the market and ongoing studies for other indications, the company is well-positioned for future growth and has a strong likelihood of success. Although there are some risks, such as potential competition and the need for additional financing, the company's solid financial standing and strong management team make it a solid investment opportunity.
Bears say
Liquidia is in a promising market position as it continues to develop and commercialize products for the treatment of pulmonary hypertension (PH) and other related diseases. However, while its lead candidate Yutrepia has the potential to be a blockbuster drug, there is still a lack of penetration in this market, and competition from other innovative treatments could limit its growth potential. Additionally, the uncertainty surrounding patent infringement lawsuits and the potential for monetary penalties or injunctions could pose risks to the company's financials. Overall, while Liquidia has potential for growth, there are significant uncertainties and challenges that could impact its stock performance.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares